Biotalys Reports Full-Year 2024 Financial Results and Business Highlights
Biotalys, an Agricultural Technology (AgTech) company developing protein-based biocontrols for sustainable crop protection, has announced key business achievements and consolidated financial results for 2024, prepared in accordance with IFRS as adopted by the European Union, and an outlook for 2025. The annual report, including the full financial report, will be published on the company’s website on 21 March 2025.
Kevin Helash, Chief Executive Officer of Biotalys, stated: “Biotalys continued to lead the charge toward creating effective and sustainable crop protection products in 2024. While we worked closely with regulators to progress the potential approval for innovative protein-based biocontrols like EVOCA, we also strengthened our platform, pipeline, partnerships, and team. Additionally, we optimized capital resources last year, achieving a significant reduction in operating expenses while strengthening our balance sheet through a successful private placement. Looking ahead, we plan to further advance our product portfolio and develop novel modes of action, as well as expand options to scale and produce our biobased solutions.”
Highlights
In 2024, Biotalys continued to cement its role as a primary innovator in the biocontrol space by advancing its technology platform and product development pipeline.
Product Pipeline:
Biotalys worked closely with the EPA (Environmental Protection Agency) in the United States and the Dutch CTGB (College voor de Toelating van Gewasbeschermingsmiddelen en Biociden) in Europe on EVOCA’s regulatory review throughout the year.
While the regulatory landscape in the United States is evolving, Biotalys has recently received a request for additional information from the EPA. The company expects to provide the EPA with the requested data in Q2, positioning EVOCA for potential registration thereafter.
In Europe, the CTGB recently recommended the approval of EVOCA’s active ingredient throughout the European Union after previously granting approval to test EVOCA in large-scale demonstration trials in the Netherlands and offer the harvest for sale for human consumption. A registration in Europe would allow first access to this important market for Botrytis and powdery mildew fungicides estimated to be around USD 1 billion at the grower level.
In addition, the company obtained patents for EVOCA from both the European Patent Office (EPO) and the United States Patent and Trademark Office (USPTO) in 2024, and from the Brazilian National Institute of Industrial Property (INPI) in February 2025. In Brazil, the patent examination process benefited from the Patentes Verdes (“Green Technology”) initiative to accelerate the examination of patent applications relating to technologies having a positive impact on the environment.
In March last year, Biotalys announced a partnership with Novonesis to advance EVOCA NG to the final stage of development. Pending success in this final development stage, the agreement secured Novonesis as the global manufacturing partner for EVOCA NG while granting it certain distribution rights. By year-end, substantial progress had been achieved in strain engineering for EVOCA NG, paving the way for the next phase of development
Biotalys also began field trials in both Europe and the United States for BioFun-6, a biofungicide candidate targeting Botrytis, powdery mildew and potentially other fungal diseases in high-value fruits and vegetables. Results published in March 2025, showed that the BioFun-6 AGROBODY biocontrol can achieve the same level of performance as EVOCA at significantly lower dosage rates, highlighting the increased potency of the new candidate.
In October, Biotalys introduced a new biofungicide program, BioFun-8, focusing on combatting Alternaria, a top leaf spot fungus, in fruits, vegetables and potato crops, and representing a global market opportunity of approximately USD 1.1 billion at grower level.
Early in the year, Biotalys also expanded its relationships with top academics, adding collaborations with leading plant science researchers for BioFun-4, targeting Phytophthora infestans, and for BioFun-7, a project in collaboration with the Gates Foundation and targeting leafspot disease. With these collaborations the company continues to build on the strong scientific foundation of its R&D programs and technology, creating synergies between the expertise and excellent research in academia and industry.
Biotalys also continued to advance its first bioinsecticide, BioIns-2, in collaboration with Syngenta Crop Protection.
Read more at Biotalys.
Get The Newsletter Today!
